HCV Reactivation in a Patient with Hepatocellular Carcinoma Due to Sorafenib: A Case Report

HCV Reactivation in a Patient with Hepatocellular Carcinoma Due to Sorafenib: A Case Report

Jun Cheng,&ast; Jinjin Pan,&ast; Dongmei Zhao, Xuejiao Ma, Qiulin Sun, Jiabin Li Department of Infectious Disease, The First Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Jiabin Li, Tel...

Full description

Bibliographic Details
Main Authors:	Cheng J, Pan J, Zhao D, Ma X, Sun Q, Li J
Format:	Article
Language:	English
Published:	Dove Medical Press 2024-02-01
Series:	International Medical Case Reports Journal
Subjects:	hepatocellular carcinoma sorafenib hcv-rna anti-hcv therapy reactivation
Online Access:	https://www.dovepress.com/hcv-reactivation-in-a-patient-with-hepatocellular-carcinoma-due-to-sor-peer-reviewed-fulltext-article-IMCRJ

Similar Items

Sorafenib, a systemic therapy for hepatocellular carcinoma
by: Nahum Méndez-Sánchez;, et al.
Published: (2008-01-01)

The distribution of hepatitis C virus genotypes in patients with hepatocellular carcinoma
by: Ayfer Bakır, et al.
Published: (2019-10-01)

Hepatocellular carcinoma in a non-cirrhotic liver of a HCV-positive woman with sustained viral response
by: Gianfranco Costanzo, et al.
Published: (2011-01-01)

Hepatocellular carcinoma in a non-cirrhotic liver of a HCV-positive woman with sustained viral response
by: Lorenzo Nosotti, et al.
Published: (2011-10-01)

Treatment of Recurrent Hepatocellular Carcinoma with Sorafenib in a HIV/HCV Co-Infected patient in HAART: A Case Report
by: De Nardo Pasquale, et al.
Published: (2012-06-01)

Definition of HCV Reactivation [Letter]
by: Kaya A, et al.
Published: (2021-10-01)

The Cyclophilin Inhibitor Rencofilstat Decreases HCV-Induced Hepatocellular Carcinoma Independently of Its Antiviral Activity
by: Winston Stauffer, et al.
Published: (2023-10-01)

Gene expression profiling of circulating CD133+ cells of hepatocellular carcinoma patients associated with HCV infection
by: Abdel-Rahman N. Zekri, et al.
Published: (2017-03-01)

Feasibility of anti-HCV reflex HCV Ag screening strategy in an HCV endemic community
by: Wei-Ming Chen, et al.
Published: (2021-05-01)

Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience
by: Omar Abdel-Rahman, et al.
Published: (2014-03-01)

MicroRNA 21as a novel biomarker in hepatitis C virus-related hepatocellular carcinoma
by: Maha Assem Hussein, et al.
Published: (2022-07-01)

Sorafenib in the treatment of advanced hepatocellular carcinoma
by: Mousa Ali
Published: (2008-01-01)

Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis
by: Nelson Cheinquer, et al.

Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives
by: Hsu CH, et al.
Published: (2014-06-01)

Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens
by: Ghias Un Nabi Tayyab, et al.
Published: (2020-04-01)

Comparative studies in detection of anti-HCV antibodies using Abbott IMx HCV, Serodia-HCV and DETECT-HCVTM
by: Nisarat Apichartpiyakul, et al.
Published: (2010-01-01)

The Utility of ANTI-HCV S/CO Ratio, HCV-RNA and ALT Test in Predicting Viremia in ANTI-HCV Positive Patients
by: Tuğrul Himmetoğlu, et al.
Published: (2007-07-01)

Concept of HBV and HCV as a risk factor and prevention of viral hepatitis-related hepatocellular carcinoma
by: Athraa Falah Alshimerry, et al.
Published: (2023-01-01)

CpG Island Methylation of Suppressor of Cytokine Signaling-1 Gene Induced by HCV Is Associated With HCV-Related Hepatocellular Carcinoma
by: Miao Liu, et al.
Published: (2022-06-01)

Comparative RNA-Sequencing Analysis Reveals High Complexity and Heterogeneity of Transcriptomic and Immune Profiles in Hepatocellular Carcinoma Tumors of Viral (HBV, HCV) and Non-Viral Etiology
by: Liliana Paslaru, et al.
Published: (2022-12-01)

Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma
by: Jun-Kyu Byun, et al.
Published: (2022-03-01)

Effect of combined siRNA of HCV E2 gene and HCV receptors against HCV
by: Ashfaq Usman Alli A, et al.
Published: (2011-06-01)

Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma
by: Liu KC, et al.
Published: (2020-08-01)

Severe Fatigue is an Important Factor in the Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib
by: Qiu X, et al.
Published: (2020-09-01)

Roles and Mechanisms of Ferroptosis in Sorafenib Resistance for Hepatocellular Carcinoma
by: Liu R, et al.
Published: (2024-12-01)

Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma
by: Saleh A. Alqahtani, et al.
Published: (2021-11-01)

Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma
by: Ting Sun, et al.
Published: (2017-11-01)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
by: Qinqin Liu, et al.
Published: (2021-10-01)

HCV core antigen is an alternative marker to HCV RNA for evaluating active HCV infection: implications for improved diagnostic option in an era of affordable DAAs
by: Rujipat Wasitthankasem, et al.
Published: (2017-11-01)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
by: Yen-Yang Chen, et al.
Published: (2020-11-01)

Sieroprevalenza di infezione da HBV e HCV tra pazienti in dialisi
by: Rosa Anna Leone, et al.
Published: (2003-12-01)

Comparison of Inflammatory Indexes in Patients Treated with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Center Observational Study
by: Havva Yeşil Çınkır, et al.
Published: (2020-04-01)

Successful two-stage operation for esophageal necrosis due to proton beam therapy followed by sorafenib in a case of large hepatocellular carcinoma
by: Eiji Higaki, et al.
Published: (2020-06-01)

Adverse Event Profile in Advance Hepatocellular Carcinoma treated with Sorafenib Presenting to CMH Rawalpindi
by: Masaba Masood, et al.
Published: (2023-08-01)

Prevalence and characteristics of hepatitis C virus infection in Shenyang City, Northeast China, and prediction of HCV RNA positivity according to serum anti-HCV level: retrospective review of hospital data
by: Yurong Li, et al.
Published: (2020-03-01)

Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea
by: Sojung Han, et al.
Published: (2024-01-01)

De novo lipogenesis is elicited dramatically in human hepatocellular carcinoma especially in hepatitis C virus‐induced hepatocellular carcinoma
by: Shaojian Li, et al.
Published: (2020-09-01)

The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma
by: Xinyao Hu, et al.
Published: (2021-07-01)

Most common HCV genotypes in patients from north-eastern Croatia
by: Magdalena Perić, et al.
Published: (2014-05-01)

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
by: Po‐Yao Hsu, et al.
Published: (2022-01-01)